CompletedPhase 2/3

Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients

Thailand358 participantsStarted 2021-01-15

Plain-language summary

This study aims to determine the efficacy of montelukast in reducing the incidence of dengue warning signs in adult dengue patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * at least 18 years old * diagnosis of dengue * positive NS1 antigen or polymerase chain reaction (PCR) test Exclusion Criteria: * any warning sign of dengue * concurrent diagnosis of other causes of fever, such as malaria or heat stroke * pregnancy * being unable to take medication by mouth * critical illness needing intubation or admission to an intensive care unit * being unable to communicate * other indication of montelukast

What they're measuring

Rate of dengue with warning signs

Timeframe: 14 days or until the discontinuation of the follow up appointment by the attending physicians, whichever is shorter.

Trial details

NCT IDNCT04673422

SponsorPhramongkutklao College of Medicine and Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-06-17

View on ClinicalTrials.gov More Dengue trials